Stocks Listing
BEAM

Beam Therapeutics Inc.

Share
BEAM
$44.28 3.11%Last Updated Nov 25 2022 08:56 PM
1D Low / 1D High
Low:$44.05
High:$45.47
1D
3.11%
5D
4.4 %
30D
11.58 %
BulletPurple
Market Cap
$3,120,367,360
3.11 %
3.1 B
BulletBlue
Volume 1D
206,774
-
206.8 K
BulletOrange
Circulating Supply
70,469,001 BEAM
70.5 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Opened
NMS
NASDAQ Stock Exchange
USA
Closes in
4 hours, 55 minutes
Working Hours
Mon-Fri, 02:30 PM - 09:00 PM
Timezone
GMT+0